| IGF signaling contributes to malignant transformation of hematopoietic progenitors by the MLL-AF9 oncoprotein. Jenkins C.R., Shevchuk O.O., Giambra V., Lam S.H., Carboni J.M., Gottardis M.M., Holzenberger M., Pollak M., Humphries R.K., Weng A.P.
Exp. Hematol. 40:715-723.e6(2012) · Mapped (4) |
| A tripartite complex composed of ETV6-NTRK3, IRS1 and IGF1R is required for ETV6-NTRK3-mediated membrane localization and transformation. Tognon C.E., Martin M.J., Moradian A., Trigo G., Rotblat B., Cheng S.W., Pollard M., Uy E., Chow C., Carboni J.M. et al.
Oncogene 31:1334-1340(2012) · Mapped (20) |
| High IGF-IR activity in triple-negative breast cancer cell lines and tumorgrafts correlates with sensitivity to anti-IGF-IR therapy. Litzenburger B.C., Creighton C.J., Tsimelzon A., Chan B.T., Hilsenbeck S.G., Wang T., Carboni J.M., Gottardis M.M., Huang F., Chang J.C. et al.
Clin. Cancer Res. 17:2314-2327(2011) · Mapped (12) |
| Proline isosteres in a series of 2,4-disubstituted pyrrolo[1,2-f][1,2,4]triazine inhibitors of IGF-1R kinase and IR kinase. Sampognaro A.J., Wittman M.D., Carboni J.M., Chang C., Greer A.F., Hurlburt W.W., Sack J.S., Vyas D.M.
Bioorg. Med. Chem. Lett. 20:5027-5030(2010) · UniProtKB (1) |
| Insulin receptor (IR) pathway hyperactivity in IGF-IR null cells and suppression of downstream growth signaling using the dual IGF-IR/IR inhibitor, BMS-754807. Dinchuk J.E., Cao C., Huang F., Reeves K.A., Wang J., Myers F., Cantor G.H., Zhou X., Attar R.M., Gottardis M. et al.
Endocrinology 151:4123-4132(2010) · Mapped (4) |
| BMS-754807, a small molecule inhibitor of insulin-like growth factor-1R/IR. Carboni J.M., Wittman M., Yang Z., Lee F., Greer A., Hurlburt W., Hillerman S., Cao C., Cantor G.H., Dell-John J. et al.
Mol. Cancer Ther. 8:3341-3349(2009) · Mapped (22) |
| Discovery of a 2,4-disubstituted pyrrolo[1,2-f][1,2,4]triazine inhibitor (BMS-754807) of insulin-like growth factor receptor (IGF-1R) kinase in clinical development. Wittman M.D., Carboni J.M., Yang Z., Lee F.Y., Antman M., Attar R., Balimane P., Chang C., Chen C., Discenza L. et al.
J. Med. Chem. 52:7360-7363(2009) · UniProtKB (1) |
| Constitutively active type I insulin-like growth factor receptor causes transformation and xenograft growth of immortalized mammary epithelial cells and is accompanied by an epithelial-to-mesenchymal transition mediated by NF-kappaB and snail. Kim H.J., Litzenburger B.C., Cui X., Delgado D.A., Grabiner B.C., Lin X., Lewis M.T., Gottardis M.M., Wong T.W., Attar R.M. et al.
Mol. Cell. Biol. 27:3165-3175(2007) · Mapped (3) |
| Tumor development by transgenic expression of a constitutively active insulin-like growth factor I receptor. Carboni J.M., Lee A.V., Hadsell D.L., Rowley B.R., Lee F.Y., Bol D.K., Camuso A.E., Gottardis M., Greer A.F., Ho C.P. et al.
Cancer Res. 65:3781-3787(2005) · Mapped (4) |
| Use of a photoactivatable taxol analogue to identify unique cellular targets in murine macrophages: identification of murine CD18 as a major taxol-binding protein and a role for Mac-1 in taxol-induced gene expression. Bhat N., Perera P.Y., Carboni J.M., Blanco J., Golenbock D.T., Mayadas T.N., Vogel S.N.
J. Immunol. 162:7335-7342(1999) · Mapped (24) |
| Transforming growth factor-beta 1 induces transforming growth factor-alpha promoter activity and transforming growth factor-alpha secretion in the human colon adenocarcinoma cell line FET. Lynch M.J., Pelosi L., Carboni J.M., Merwin J., Coleman K., Wang R.C., Lin P.F., Henry D.L., Brattain M.G.
Cancer Res. 53:4041-4047(1993) · UniProtKB (1) |
| Properties of the 120,000- and 95,000-dalton actin-binding proteins from Dictyostelium discoideum and their possible functions in assembling the cytoplasmic matrix. Condeelis J., Vahey M., Carboni J.M., DeMey J., Ogihara S.
J. Cell Biol. 99:119-126(1984) · UniProtKB (1) · Mapped (1) |
| Ligand-induced changes in the location of actin, myosin, 95K (alpha-actinin), and 120K protein in amebae of Dictyostelium discoideum. Carboni J.M., Condeelis J.S.
J. Cell Biol. 100:1884-1893(1985) · Mapped (3) |
